{"nct_id":"NCT05280314","title":"Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors","status":"RECRUITING","status_verified_date":"2024-03","start_date":"2023-12-21","start_date_type":"ACTUAL","primary_completion_date":"2025-04-30","primary_completion_date_type":"ESTIMATED","completion_date":"2027-01","completion_date_type":"ESTIMATED","phases":["PHASE2"],"tickers":["IOBT"]}